The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Coronary CT Angiography and 5-Year Risk of Myocardial Infarction
Open accessAbstract
BACKGROUND: Although coronary computed tomographic angiography (CTA) improves diagnostic certainty in the assessment of patients with stable chest pain, its effect on 5-year clinical outcomes is unknown. METHODS: In an open-label, multicenter, parallel-group trial, we randomly assigned 4146 patients with stable chest pain who had been referred to a cardiology clinic for evaluation to standard care plus CTA (2073 patients) or to standard care alone (2073 patients). Investigations, treatments, and clinical outcomes were assessed over 3 to 7 years of follow-up. The primary end point was death from coronary heart disease or nonfatal myocardial infarction at 5 years. RESULTS: The median duration of follow-up was 4.8 years, which yielded 20,254 patient-years of follow-up. The 5-year rate of the primary end point was lower in the CTA group than in the standard-care group (2.3% [48 patients] vs. 3.9% [81 patients]; hazard ratio, 0.59; 95% confidence interval [CI], 0.41 to 0.84; P=0.004). Although the rates of invasive coronary angiography and coronary revascularization were higher in the CTA group than in the standard-care group in the first few months of follow-up, overall rates were similar at 5 years: invasive coronary angiography was performed in 491 patients in the CTA group and in 502 patients in the standard-care group (hazard ratio, 1.00; 95% CI, 0.88 to 1.13), and coronary revascularization was performed in 279 patients in the CTA group and in 267 in the standard-care group (hazard ratio, 1.07; 95% CI, 0.91 to 1.27). However, more preventive therapies were initiated in patients in the CTA group (odds ratio, 1.40; 95% CI, 1.19 to 1.65), as were more antianginal therapies (odds ratio, 1.27; 95% CI, 1.05 to 1.54). There were no significant between-group differences in the rates of cardiovascular or noncardiovascular deaths or deaths from any cause. CONCLUSIONS: In this trial, the use of CTA in addition to standard care in patients with stable chest pain resulted in a significantly lower rate of death from coronary heart disease or nonfatal myocardial infarction at 5 years than standard care alone, without resulting in a significantly higher rate of coronary angiography or coronary revascularization. (Funded by the Scottish Government Chief Scientist Office and others; SCOT-HEART ClinicalTrials.gov number, NCT01149590 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The SCOT-HEART trial (Scottish Computed Tomography of the Heart) was an open-label randomized comparison of CTA with standard care (which could include stress testing, angiography, or continued medical management) in 4146 subjects with stable chest pain (444 with diabetes mellitus) from 2010 to 2014.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [230]
In the citing paper
“Revascularization rates were similar in the 2 groups and probably did not play a major role in the difference between the groups in the rate of the primary end point.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [230]
In the citing paper
“This effect was similar in the subset of patients with diabetes mellitus (primary end point HR, 0.36 [95% CI, 0.15–0.87]).”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [230]
In the citing paper
“This difference was caused primarily by a lower rate of nonfatal myocardial infarction in the CTA group than in the standard care group (HR, 0.60 [95% CI, 0.41–0.87]).”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [230]
In the citing paper
“At the 5-year follow-up, the rate of the composite end point of death caused by CAD or nonfatal myocardial infarction was lower in the CTA group than in the standard care group (2.3% versus 3.9%; HR, 0.59 [95% CI, 0.41–0.84]; P=0.004).”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [230]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 3×
“Beta-blocker 1357/4142 (33) 672/2070 (32) 685/2072 (33)”
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Long-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999 · cited 2×
“Beta-blocker 1357/4142 (33) 672/2070 (32) 685/2072 (33)”
Diagnostic Performance of Coronary Angiography by 64-Row CT
Miller, J. M., Rochitte, C. E., Dewey, M., Arbab‐Zadeh, A., Niinuma, H., Gottlieb, I., Paul, N., Clouse, M. E., Shapiro, E. P., Hoe, J. W. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806576 · Cited by 1,806
Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease
Douglas, P. S., Hoffmann, U., Patel, M. R., Mark, D. B., Al-Khalidi, H. R., Cavanaugh, B., Cole, J., Dolor, R. J., Fordyce, C. B., Huang, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415516 · Cited by 1,543
Aspirin, Sulfinpyrazone, or Both in Unstable Angina
Cairns, J. A., Gent, M., Singer, J., Finnie, K., Froggatt, G. M., Holder, D. A., Jablonsky, G., Kostuk, W. J., Meléndez, L. J., Myers, M. G., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198511283132201 · Cited by 1,126
Flagged first, then by citations
Cited by
Sorted by citations
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C. J., Andreotti, F., Koskinas, K. C., Rosselló, X., Adamo, M., Ainslie, J., BANNING, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 3,521
The changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873
2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease
Pelliccia, A., Sharma, S., Gati, S., Bäck, M., Börjesson, M., Caselli, S., Collet, J.-P., Corrado, D., Drezner, J. A., Halle, M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa605 · Cited by 1,958
Metadata
- Authors
- The SCOT-HEART Investigators
- Affiliations
- University of Edinburgh (GB)
- Corresponding author
- The SCOT-HEART Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-09-06
- Volume
- 379
- Issue
- 10
- Pages
- 924-933
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2892274298
- Cited by
- 1,390
- References
- 32
- Citations by year
- 2026: 138 · 2025: 159 · 2024: 171 · 2023: 197 · 2022: 164 · 2021: 211 · 2020: 182 · 2019: 142 · 2018: 26
- FWCI
- 96.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- Chief Scientist Office (CZH/4/588)
- British Heart Foundation (CH/09/002, RE/13/3/30183)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- coronary CT angiography, myocardial infarction, coronary heart disease mortality, stable chest pain, coronary revascularization, invasive coronary angiography, prophylaxis, antianginal therapy, coronary artery disease diagnosis, standard of care comparison, cardiovascular risk stratification
- MeSH terms
- Computed Tomography Angiography, Adult, Aged, Chest Pain, Coronary Disease, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Risk, Incidence, Coronary Angiography, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
